The Medical Letter on Drugs and Therapeutics
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved reslizumab (Cinqair – Teva), a humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for add-on maintenance treatment of severe asthma in adults who have an eosinophilic phenotype. It is the second IL-5 antagonist to be approved in the US; mepolizumab (Nucala) was approved for the same indication in 2015.1

EOSINOPHILIC PHENOTYPE — What constitutes an eosinophilic phenotype is not well defined, but patients with this phenotype generally have severe disease with high eosinophil levels in blood and/or sputum despite treatment with a corticosteroid.2

OTHER MONOCLONAL ANTIBODIES — In clinical trials, mepolizumab reduced exacerbations and the need for maintenance oral corticosteroids in patients with severe asthma and high eosinophil counts. The recombinant humanized ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Reslizumab (Cinqair) for Severe Eosinophilic Asthma
Article code: 1497d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian